LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

Search

BioCryst Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

7.62 -0.13

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

7.55

Max

7.62

Pagrindiniai rodikliai

By Trading Economics

Pajamos

5.1M

5.1M

Pardavimai

18M

163M

Pelno marža

3.113

Darbuotojai

580

EBITDA

7.2M

28M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+129.36% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-11-03

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-172M

1.7B

Ankstesnė atidarymo kaina

7.75

Ankstesnė uždarymo kaina

7.62

Naujienos nuotaikos

By Acuity

50%

50%

132 / 371 reitingas Healthcare

BioCryst Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-09-26 18:25; UTC

Pagrindinės rinkos jėgos

Mirion Technologies Stock Rises on Expanded Notes, Shares Offerings

2025-09-27 07:00; UTC

Uždarbis

This Water Stock Is Dehydrated. What Could Bring It Back. -- Barrons.com

2025-09-27 04:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-09-26 21:56; UTC

Įsigijimai, susijungimai, perėmimai

Staar Surgical, Insight Enterprises, and More Stocks See Action From Activist Investors -- Barrons.com

2025-09-26 20:54; UTC

Uždarbis

U.S. TikTok for $14 Billion? Making Sense of the Bargain-Basement Price. -- Barrons.com

2025-09-26 20:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2025-09-26 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-09-26 20:27; UTC

Įsigijimai, susijungimai, perėmimai

Electronic Arts Stock Pops on Report Videogame Maker Is Close to Going Private -- Barrons.com

2025-09-26 20:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-09-26 19:54; UTC

Rinkos pokalbiai

Canada's Can't-Build Reputation Is Somewhat Earned -- Market Talk

2025-09-26 19:53; UTC

Įsigijimai, susijungimai, perėmimai

Electronic Arts Stock Pops on Report Videogame Maker Is Close to Going Private -- Barrons.com

2025-09-26 19:40; UTC

Uždarbis

The U.S. TikTok Is Apparently Fetching a Bargain-Basement Price. A Few Reasons Why. -- Barrons.com

2025-09-26 19:24; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Mixed As October Expires -- Market Talk

2025-09-26 19:17; UTC

Rinkos pokalbiai

Oil Posts Weekly Gains on Russia-Ukraine Tensions -- Market Talk

2025-09-26 19:15; UTC

Rinkos pokalbiai

AI Deployment Beginning to Weigh on Job Creation, Former Central Banker Says -- Market Talk

2025-09-26 19:03; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-09-26 19:03; UTC

Rinkos pokalbiai

Gold Fuels Stellar Performance in Toronto Stock Market -- Market Talk

2025-09-26 18:50; UTC

Rinkos pokalbiai
Uždarbis

Costco's Executive Membership Gains Seen as Offsetting Slower Renewal Rates -- Market Talk

2025-09-26 18:36; UTC

Rinkos pokalbiai

Silver Closes Out Week With Strong Surge -- Market Talk

2025-09-26 18:02; UTC

Įsigijimai, susijungimai, perėmimai

ING: Continue Working Towards Completing Transaction, Exit From Russian Market >ING

2025-09-26 18:02; UTC

Įsigijimai, susijungimai, perėmimai

ING: Global Development Hasn't Received All Necessary Approvals >ING

2025-09-26 18:02; UTC

Įsigijimai, susijungimai, perėmimai

ING: No Realistic Prospect of Completing Sale of ING Bank (Eurasia) to Global Development in 3Q

2025-09-26 17:54; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Rises For Fifth Straight Week -- Market Talk

2025-09-26 16:56; UTC

Rinkos pokalbiai
Uždarbis

Costco Increasingly Challenged to Meet Lofty Expectations -- Market Talk

2025-09-26 16:41; UTC

Rinkos pokalbiai
Uždarbis

Costco's Valuation Seen as Too High Amid Slow Down -- Market Talk

2025-09-26 16:26; UTC

Uždarbis

Correction to Sherwin-Williams Extends Losses. What's Ailing the Paint Maker. -- Barrons.com

2025-09-26 16:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-09-26 16:12; UTC

Rinkos pokalbiai

Nike Stock Seen With Limited Upside -- Market Talk

2025-09-26 15:59; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-09-26 15:59; UTC

Rinkos pokalbiai

Nike Seen Showing Progress in Turnaround -- Market Talk

Akcijų palyginimas

Kainos pokytis

BioCryst Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

129.36% į viršų

12 mėnesių prognozė

Vidutinis 17.5 USD  129.36%

Aukščiausias 30 USD

Žemiausias 12 USD

Remiantis 6 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines BioCryst Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

6 ratings

6

Pirkti

0

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

132 / 371 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
help-icon Live chat